8.68 USD
↗ 0.28 (3.33%)AT CLOSE (11:59 AM EDT)
Arvinas, Inc
ARVNNASDAQ • USD
8.45
↘ 0.23 (2.71%)
POST MARKET (AS OF 07:58 PM EDT)
Post Market
AS OF 07:58 PM EDT
8.45
↘ 0.23 (2.71%)
Market: CLOSED
Shares of Arvinas, Inc (ARVN) are trading at $8.69. The stock presents a mixed profile: our models indicate a Strong Buy for technical indicators, while underlying fundamentals flash a Sell. This is driven by a concerning Altman Z-Score in the distress zone, negative Return on Equity and a bearish Death Cross on the long-term moving averages. On valuation, ARVN trades roughly in line with sector averages — neither particularly cheap nor expensive.
Technical & fundamental data as of Aug 6, 2026.
Open?$8.40
High?$8.72
Low?$8.37
Prev. Close?$8.40
Volume?2.6M
Avg. Volume?812.8K
VWAP?$8.49
Rel. Volume?3.18x
Bid / Ask
Bid?$8.28 × 200
Ask?$8.68 × 1.0K
Spread?$0.40
Midpoint?$8.48
Valuation & Ratios
Market Cap?542.0M
Shares Out?64.5M
Float?52.0M
Float %?80.6%
P/E Ratio?N/A
P/B Ratio?1.40
EPS?-$3.43
Dividend?0.00%
Ex-Dividend?N/A
News
Profile
Arvinas Inc is a clinical-stage biotechnology company focused on improving the lives of patients suffering from debilitating and life-threatening diseases through the discovery, development, and commercialization of therapies that degrade disease-causing proteins. The company is using its PROteolysis TArgeting Chimera, a protein degradation platform, to develop therapeutics designed to harness the body's own natural protein disposal system to selectively and efficiently degrade and remove disease-causing proteins. Its clinical development program includes various product candidates such as ARV-102, ARV-806, ARV-393, ARV-027, and vepdegestrant, in their different stages of development, being developed to target certain harmful proteins causing oncology and neurology-related diseases.
Themes
Employees
246
Market Cap
542.0M
Industry
PHARMACEUTICAL PREPARATIONS
Website
Listed
2018-09-27
Address
395 WINCHESTER AVE
NEW HAVEN, CT 06511
Phone: 203-535-1456
NEW HAVEN, CT 06511
Phone: 203-535-1456
Technical OutlookStrong Buy
Strong SellNeutralStrong Buy
Long-Term (Tide)?▲ Bullish(+1/3)
Medium-Term (Wave)?▲ Bullish(+3/3)
Short-Term (Ripple)?▲ Bullish(+3/3)
MA Alignment?Mixed
Full Technical Analysis →Fundamental OutlookSell
Strong SellNeutralStrong Buy
F-Score?23
Z-Score?0
Momentum?50
Short Sent.?39
Piotroski F-Score?3/9Weak
Altman Z-Score?-2.56Distress
Confidence?63%Moderate
Short InterestHigh
Short % of Float?7.66%Elevated
Short Interest?4.0M
Days to Cover?6.6
Free Float52.0M
Avg Daily Volume601.3K
Settlement Date2026-07-15
Financial Health
Current Ratio?5.44Strong
Quick Ratio?5.44Strong
Cash Ratio?0.75Adequate
Debt/Equity?0.00Low
ValuationATTRACTIVELY VALUEDvs 1 peers + S&P 500
Score83/100
P/E?N/A▾
P/B?1.40CHEAP▾
Peers100
S&P89
P/S?6.06FAIR▾
Peers100
S&P22
P/FCF?N/A▾
EV/EBITDA?-1.8CHEAP▾
S&P97
EV/Sales?5.09FAIR▾
Peers100
S&P35
Returns & Efficiency
ROE?-57.2%WEAK▾
S&P3
ROA?-34.2%WEAK▾
S&P3
Cash Flow & Enterprise
FCF?$-256900000
Enterprise Value?$455.0M
Fundamentals ratios updated end of day